M.C.Hayes, B.R. Birch, A.J. Cooper and J.N. Primrose [ Departments of Urology and University Department of Surgery, Southampton General Hospital, Southampton, UK]
Cellular Resistance to Mitomycin C is Associated with Overexpression of MDR-1 in a Urothelial Cancer Cell Line [ MGH-U1]
BJU International, volume 87, Number 3, February 2001, Pg.Nos. 245-250
Conclusion – Urothelial cancer cell resistance to mitomycin C is associated with cross resistance to epirubicin and overexpression of MDR-1, suggesting that mitomycin C falls within the MDR category. Clinical application of this methodology may allow patients to be identified who are unlikely to benefit from intravesical chemotherapy.
O.D.M. Hughes, A.C. Perkins, et al [ Departments of Urology and Pathology, City Hospital, Nottingham, and Department of Medical Physics and Cancer Research Laboratory, School of Pharmaceutical Sciences, University of Nottingham, UK]
Imaging for Staging Bladder Cancer : a Clinical Study of Intravenous 111 Indium-labelled Anti-MUC1 Mucin Monoclonal Antibody C595
BJU International, volume 87, Number 1, January 2001, Pg.Nos. 39-46
Accurate tumor staging is important in determining the clinical management and prognosis of bladder cancer. Radical radiotherapy or cystectomy for muscle invasive bladder cancer has a good chance of cure for disease confined to the bladder. However staging methods like CT scan and MRI may be inaccurate in upto 40% of patients.
The objective of this study was to investigate the clinical application of an 111. In labelled anti-MUC1 mucin monoclonal antibody [mAB] imaging for staging invasive bladder cancer.
Methods – Indirect immunohistochemistry was used to confirm the expression of the MUC1 target antigen by metastatic tumours. 12 patients with bladder cancer [ 2 superficial and 10 with locally invasive/metastatic disease] underwent planar
g-scintigraphy 48h after an intravenous injection with 111. In labelled anti-MUC1 mucin mAb C595.
Results – No bladder uptake was seen in 2 patients with superficial disease, but scintigraphy showed primary and recurrent bladder tumours and metastases in nine of the remaining 10 patients with invasive disease. In three patients additional staging information was obtained from the mAb imaging which would have altered patient management. There were no reported side-effects.
Conclusion – This study confirmed the ability of the mAb technique to detect both primary and recurrent invasive bladder tumours and distant metastases. Some lesions shown by mAb imaging were not detected by other methods. mAb imaging has the ability to improve clinical staging and assist in selecting those patients most likely to benefit from radical therapy.